Abstract

Objective. This study aimed to investigate the value of lung ultrasound images in evaluating the efficacy of budesonide combined with pulmonary surfactant (PS) in the treatment of neonatal respiratory distress syndrome (NRDS) in premature infants. Methods. 76 NRDS premature infants admitted to the hospital were randomly divided into experimental group and control group, with 38 children in each group. The premature infants in control group underwent PS, and those in experimental group underwent budesonide combined with PS. After treatment, lung ultrasound imaging was used to evaluate the curative effect, and X-ray results were used as a reference. The changes in clinical signs of two groups were detected, and the pulmonary ultrasound was used to evaluate the clinical efficacy of two groups. The changes in the lung ultrasound score (LUS) and arterial blood gas (ABG) indexes of two groups were compared before and after treatment. Results. LUS and improvement of patients of experimental group were obviously higher than those of the control group after treatment. LUS of experimental group was 12.1 ± 3.7, and that of control group was 18.2 ± 2.3, respectively. The differences were statistically significant ( P < 0.05). The arterial partial oxygen pressure (PaO2) and oxygenation index (PaO2/FiO2) levels of two groups of patients increased dramatically after treatment. PaO2 and PaO2/FiO2 levels of experimental group were 65.59 ± 12.46 mmHg and 112.57 ± 19.3 mmHg, and those of control group were 45.12 ± 11.21 mmHg and 101.28 ± 21.36 mmHg, respectively. However, arterial partial pressure of carbon dioxide (PaCO2) level was significantly decreased in two groups after treatment. PaCO2 level of experimental group was 40.24 ± 8.92 mmHg, and that of control group was 41.22 ± 9.24 mmHg, respectively ( P < 0.05). The diagnostic accuracy of lung ultrasound images in two groups was 95.3% and 96.2%, respectively. Conclusion. Pulmonary ultrasonography showed a high diagnostic accuracy in evaluating the efficacy of budesonide combined with PS in the treatment of NRDS in premature infants. It can evaluate the cardiopulmonary function of premature infants with NRDS and effectively improve the respiratory status of premature infants. In conclusion, this study provided some reference value for upgrading the clinical treatment of NRDS in premature infants.

Highlights

  • Neonatal respiratory distress syndrome (NRDS) is a common respiratory disease of premature infants, mainly manifested as expiratory moans, dyspnea, and other symptoms [1]

  • 76 NRDS premature infants admitted to the hospital were randomly divided into experimental group and control group, with 38 children in each group. e premature infants in control group underwent pulmonary surfactant (PS), and those in experimental group underwent budesonide combined with PS

  • It indicated that the lung ultrasound score (LUS) score and oxygenation index of all patients in this study showed a significant negative correlation, that was, the lower the oxygenation index, the higher the LUS score

Read more

Summary

Introduction

Neonatal respiratory distress syndrome (NRDS) is a common respiratory disease of premature infants, mainly manifested as expiratory moans, dyspnea, and other symptoms [1]. Studies in recent years have shown that the function of simulating PS can be achieved by supplementing similar PS externally to premature infants so as to expand the lungs of premature infants and relieve the symptoms of NRDS. Studies have confirmed that local use of glucocorticoids (GCs) can directly alleviate lung diseases. Anti-inflammatory effect of GCs such as inhibition of inflammatory mediator release and cytokine-mediated immune response may play an important role in the treatment of NRDS. A clinical study comparing the effects of inhaled and oral Bun on NRDS confirmed a significant difference between inhaled Bun and placebo, but there were no significant differences between oral Bun and placebo [4]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call